Xintela (XINT) Q2 2025 earnings summary

Executive summary

• Clinical study on knee osteoarthritis with XSTEM completed; 24-month data analysis ongoing, final results expected in September 2025.

• GMP production facility generating significant revenues, with plans for further commercialization and expansion.

• High subscription rate (96.7%) for TO3 warrants, raising SEK 10.1 million in June 2025.

• Collaboration and license agreement signed with EQGen Biomedical for veterinary stem cell products.

• Management team strengthened with appointment of new COO & VP Commercial Manufacturing.

Financial highlights

• Q2 2025 income: TSEK 872 (Q2 2024: 4); H1 2025 income: TSEK 1,012 (H1 2024: 303).

• Q2 2025 loss before tax: TSEK -12,119 (Q2 2024: -10,400); H1 2025 loss before tax: TSEK -22,780 (H1 2024: -21,773).

• Loss per share: SEK -0.02 for Q2 2025 (Q2 2024: -0.02); SEK -0.03 for H1 2025 (H1 2024: -0.04).

• Cash and cash equivalents at June 30, 2025: TSEK 10,532 (June 30, 2024: 445).

• Cash flow for Q2 2025: TSEK 4,005 (Q2 2024: -9,940); investments for Q2 2025: TSEK 70.

Outlook and guidance

• Final results from the osteoarthritis study expected in September 2025.

• Continued focus on commercialization of GMP facility and expansion into contract manufacturing.

• Financing strategy emphasizes revenue from collaborations, partnerships, licensing, and commercial manufacturing.